How effective is Ninlaro (ixazomib) for multiple myeloma?
Ninlaro is used for multiple myeloma in combination regimens, and its efficacy is shown through improved outcomes versus placebo in clinical trials.
In the pivotal trial for relapsed/refractory multiple myeloma (tour de force: NINLARO plus lenalidomide and dexamethasone vs placebo plus those same drugs), adding Ninlaro improved progression-free survival (PFS) compared with the control regimen [1]. In that study, the median PFS was 20.6 months with Ninlaro versus 14.7 months with placebo [1].
What endpoints did Ninlaro improve (PFS vs overall survival)?
The key efficacy signal reported for Ninlaro in this setting was longer progression-free survival [1]. Overall survival (OS) results were not the primary focus of that trial’s headline comparison and are typically harder to see early because many patients later receive additional effective therapies after relapse [1].
Who is it effective for: newly diagnosed vs relapsed/refractory?
Ninlaro efficacy is supported in relapsed/refractory multiple myeloma when it is combined with lenalidomide and dexamethasone [1]. Clinical use and dosing are tied to the specific combination and prior-treatment setting used in the supporting trial(s) [1].
Does Ninlaro work in patients with high-risk disease?
Efficacy in high-risk cytogenetic or clinical subgroups depends on how “high risk” is defined and how those patients behaved in the underlying studies. The trial-level headline effect still supports benefit overall, but subgroup outcomes are not the same as the overall PFS result and should be interpreted in the context of the published subgroup analyses [1].
How fast does Ninlaro show benefit?
In the NINLARO pivotal trial, the benefit was reflected in the time to disease progression as captured by the PFS comparison (median 20.6 months vs 14.7 months) [1]. That means the regimen delayed progression over the majority of time compared with placebo in that study population, rather than providing only short-lived response [1].
What matters most for efficacy in real-world use?
Because Ninlaro’s trial efficacy was demonstrated in specific combination regimens, the biggest driver of real-world “effectiveness” is whether the patient receives the same regimen components and dosing schedule used in the trial [1]. Supportive care and dose modifications for adverse events can also affect whether patients can stay on therapy long enough to see the expected PFS benefit [1].
Sources
[1] https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf